We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

Source: Pharmacy Times - Pharmacy Practice News and Expert Insights articles Post Content Read More

Source: Pharmacy Times - Pharmacy Practice News and Expert Insights articles Post Content Read More
Latest Data

Latest Publications

Prognostic and clinicopathological value of prognostic nutritional index in patients with multiple myeloma: a meta-analysis

Front Oncol. 2025 Sep 19;15:1545096. doi: 10.3389/fonc.2025.1545096. eCollection 2025. ABSTRACT...

The risk of second primary malignancies in patients receiving T-cell directed therapies for multiple myeloma: a systematic review

Leuk Lymphoma. 2025 Sep 29:1-10. doi: 10.1080/10428194.2025.2560085. Online ahead of print....

Efficacy and toxicity of treatment of smoldering multiple myeloma: a systematic review and meta-analysis

Ann Med. 2025 Dec;57(1):2560679. doi: 10.1080/07853890.2025.2560679. Epub 2025 Sep 24. ABSTRACT...

A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients

ESMO Open. 2025 Aug;10(8):105514. doi: 10.1016/j.esmoop.2025.105514. Epub 2025 Jul 15. ABSTRACT...

Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis

Haematologica. 2025 Aug 14. doi: 10.3324/haematol.2025.288174. Online ahead of print. ABSTRACT Not...

Email

info@myeloma360.com